Current news and events

Clinical trials and research projects at Oslo University Hospital related to patients with COVID-19 and SARS CoV-2 infection

On this web page you will find an overview over planned and ongoing clinical trials and other research projects at Oslo University Hospital related to COVID-19 and SARS CoV-2 infection. The information has been retrieved from applications to the regional ethics committee, the Norwegian Research Council, other funding sources, or directly from the researchers behind the projects.

Gunnveig Grødeland interviewed for Uniforum

Gunnveig Grødeland (photo Ola Gamst Sæter)
Gunnveig Grødeland (photo Ola Gamst Sæter)

Gunnveig Grødeland, leader of the "Influenza and Adaptive Immunity research group at the Department of Immunology, the Division of Laboratory Medicine, has recently been interviewed for Uniforum, the digital newspaper for the University of Oslo. In the article - entitled "Gunnveig Grødeland is trying to avert the next pandemic" - she talks about vaccines, pandemics and how she got interested in immunology.

Video award to Aleksandra Dukic

The Scientists’ Choice Award for Life Sciences Video of the Year was awarded to Dr. Aleksandra Dukic from Kjetil Taskén's Cell Signalling and Immune Regulation Group at the Institute for Cancer Research. The winning video, first published on The Scientists’ Channel, details a novel target for inhibiting glioblastoma cancer invasion into surrounding brain tissue.
Runner-up for Life Sciences Video Interview of the Year included a video interview with Dr. Theodossis Theodossiou, head of the Protonic project group, on the photodynamic treatment of cancer.

Antoni Wiedlocha funded by the EEA Poland-Norway grants

Antoni Wiedlocha
Antoni Wiedlocha
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers​", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.

The cancer patient’s own drug sensitivity model

From left: Eide, Kryeziu and Bruun.

The cancer patient’s own drug sensitivity model: researchers from the Lothe lab and collaborators recently published a paper in Clinical Cancer Research describing ex vivo patient-derived organoids from colorectal liver metastases in a heterogeneity context. 

Drs. Jarle Bruun, Kushtrim Kryeziu and Peter W. Eide (photo) were shared 1st authors , and have established the PDO lineages and drug screen analyses.

Jørgen Smeby the first to defend his PhD digitally at the Institute for Cancer Research

Jørgen Smeby during the digital PhD defence

The first digital PhD defence at the Institute for Cancer Research was held on the 20th of April 2020.

Dr. Jørgen Smeby defended his thesis "Molecular subtype-dependent impact of driver mutations in colorectal cancer" submitted to the Faculty of Medicine, University of Oslo.

The work was performed in the Lothe lab at the Institute for Cancer Research. 

The Norwegian Cancer Symposium postponed to 2021Sustainable cancer care using molecular tests - from a prostate cancer perspective

The Norwegian Cancer Symposium 2020 - "Sustainable cancer care using molecular tests - from a prostate cancer perspective" - is postponed to 2021

We have been monitoring the escalation of the COVID-19 pandemic. To give the attendance the possibility to meet you face-to-face and to ensure that everybody get the chance to join us and stay healthy and safe is of great importance.
We have therefore decided to postpone the symposium till September, 27th-28th 2021.

Registration will re-open early 2021: https://www.norprost.com

Nature Communications publication:Claudin-low – truly an intrinsic breast cancer subtype?

From left: Fougner, Bergholtz, Norum and Sørlie
From left: Fougner, Bergholtz, Norum and Sørlie

In a study published in Nature Communications April 14th, Fougner and colleagues from Therese Sørlie’s group critically investigate the claudin-low breast cancer subtype. 

Here, Fougner, Bergholtz, Norum and Sørlie scrutinize genomic, transcriptomic and clinical features in claudin-low breast tumors. 

The publication is accompanied by an "Behind the paper" blog in Nature Comms. (April 15th).


More news from the archive